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Aims: Sensory loss and impaired balance are considered risk factors of incident falls. The
aim of this study was to assess the relationship between degree of foot sensation and bal-
ance, risk of falls, incidence of fall-related injuries and costs in a cohort of patients with
diabetes.
Methods: (Non)-neuropathic subjects participating in the Rotterdam Diabetic Foot Study
were followed prospectively. Subjects underwent sensory testing of the feet (39 item Rotter-
dam Diabetic Foot Study Test Battery (RDF-39)); balance was assessed at the second follow-
up (Brief-BESTest) as were data on incident falls. Medical records and financial data were
abstracted to estimate fall-related morbidity and in-hospital costs.
Results: A higher RDF-39 score, cerebral artery disease, type 2 diabetes, height and age were
predictors of the Brief-BESTest total score. 41/296 patients (13.9%) reported two or more
falls during follow-up. Predictors for recurrent falls were a higher RDF-39 score (aOR:
1.124, p < 0.0005), male gender (aOR: 0.319, p = 0.016), age (aOR: 0.938, p = 0.003) and type
2 diabetes (aOR: 3.157, p = 0.100). Thirty-one patients used medical resources (median US
$ 440.45 (IQR: 179–1162).
Conclusions: Degree of sensory loss correlates significantly with an increased imbalance
and risk of falls. The RDF-39 may be used as stratification tool in medical decision-
making and patient information.
 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).d Surgery,
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Balance is the ability to maintain the body’s line of gravity
over its base of support. A correctly functioning balance sys-
tem allows a person to maintain a proper vision while mov-
ing, to determine the direction and speed of movement, to
identify the body’s position in its space and to make auto-
matic postural adjustments to maintain posture and stability
in varying circumstances [1].
Balance is achieved and maintained by a complex set of
sensorimotor control systems that necessitates sensory input
from vision (sight), proprioception (touch) and the vestibular
system (motion, equilibrium, spatial orientation) [2]. This
input information is integrated in the brain, together with
motor output to the eye and body muscles as effector organs.
Ageing, disease, injury and certain drugs can affect one or
more of these components, resulting in an elevated risk of bal-
ance impairment and gait disorders [3,4]. Diabetes mellitus,
for example, may affect sensory input from the feet, resulting
in an increased risk of falls, fractures and death [5,6].
One of the sequelae of diabetes is diabetic sensorimotor
polyneuropathy (DSP), which is prevalent in the diabetes pop-
ulation and associated with both neuropathic symptoms like
burning, tingling and pain, and an insidious simultaneous
process of loss of sensation at the feet [7–9]. Prevalence rates
of DSP in type 2 diabetes increase to 50% after 10 years of dis-
ease duration and in type 1 diabetes this is 20% after 20 years
[10]. Severe loss of sensation may also result in balance prob-
lems and falls [8,11]. Patients with reduced cutaneous sensa-
tion have different plantar pressure distributions compared
to healthy individuals [12]. However, little is known about
the influence of reduced sensation to balance impairment
[12–15]. To further quantify the relationship between diabetes
related sensory loss and balance impairment, we evaluated
whether the 39-item Rotterdam Diabetic Foot Study Test Bat-
tery (RDF-39), a validated instrument to grade the loss of sen-
sation, is capable of stratifying patients in high or low risk
categories of accidental falls [8,11]. The RDF-39 contains
dichotomized test items on incremental severity of sensibility
loss at the feet, ranging from loss of static- and moving two-
point discrimination to prior ulceration and amputation
[8,9,16].
The aim of this study was to assess the relationship
between degree of foot sensation and balance, risk of falls
and its consequences in terms of incident fall-related injuries
and fall-related costs in a cohort of individuals with diabetes.
2. Methods
2.1. Study design and subjects
The current study is part of the Rotterdam Diabetic Foot Study
(RDF-study), a prospective cohort study of unselected diabetes
type 1 and type 2 patients followed at the outpatient Diabetes
Clinic of the Franciscus Gasthuis & Vlietland hospital, Rotter-
dam, the Netherlands. RDF-study design and methods have
been reported in detail elsewhere[11,17]. In short, the aim of
the RDF-study is to investigate the natural history of neuropa-
thy, including deterioration of sensation of the feet. The RDF-study participants were recruited from patients visiting the
outpatient diabetes clinic. RDF-study inclusion criteria were:
diabetes mellitus (treated by oral blood glucose lowering
drugs and/or insulin), age over 18 years, no significant cogni-
tive impairment, speaking Dutch and signed informed con-
sent. Exclusion criteria were: active radicular syndrome and
neurological disease interfering with sensibility of the feet,
as assessed at the baseline interview and with the screening
questionnaire. The Medical Research Ethics Committee of
Erasmus University Medical Center, Rotterdam, the Nether-
lands approved the study (MEC-2009-148).
2.2. Data collection and tests
Baseline measurements were conducted between January
2014 and June 2015, with patients first subjected to an inter-
view (history taking (e.g. prior ulceration, amputation, comor-
bidities), Michigan Neuropathy Screening Instrument (MNSI)),
then to a physical examination (full Rotterdam Diabetic Foot
Study Test Battery) together with gathering of demographic
(age, sex), anthropometric (height, weight) and laboratory
(routine measurements) data, which was repeated in follow-
up visits 1–1.5 years later. At the second follow-up visit, bal-
ance tests (The Brief-Balance Evaluation Systems Test (Brief-
BESTest)) were performed in an unselected group of partici-
pants. Data on falls were collected at each follow-up visit
and included the circumstances of each fall, usage of medical
resources and whether hospitalization was required. Non-
fallers and recurrent fallers were distinguished. Medical
resource use and associated costs were retrieved from the
hospital’s financial systems or general practitioner. Costs
were originally estimated in Euros and later converted in
the US dollars 2016 exchange rate: one Euro equaled approx-
imately 1.11 US dollars.
2.2.1. Brief-BESTest
The primary outcome of this study was patients balance sta-
tus. The Brief-BESTest is a valid balance test that constitutes
of 6 balance control system items from the original BESTest
[18–20], referring to biomechanical constraints, stability lim-
its, sensory orientation and stability in gait. The assessor
scores each item from 0 (severe balance impairment) to 3
(no balance impairment). Two of the 6 items (transition-
anticipatory postural adjustment, reactive postural response)
are scored bilaterally, resulting in an 8-item balance test. The
score range is 0–24 points, with higher scores indicative of a
better balance performance [18,21]. The Brief-BESTest has a
high interrater (ICC = 0.86  0.96) and test-retest (ICC = 0.90
 0.98) reliability in subjects with and without neurological
diagnosis. The Brief-BESTest is able to validly discriminate
between patients with and without a history of falls (mean
total score 12.5 and 15.5, respectively) [18,19]. The Brief-
BESTest was only administered in RDF-study patients who
entered the second follow-up visit.
2.2.2. Falls
The secondary outcome of this study was the risk of falls. A
fall was defined as a person inadvertently ending up on the
ground or at a lower level [22]. Because multiple falls are asso-
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 5 8 ( 2 0 1 9 ) 1 0 7 9 3 0 3ciated with an increased risk of falling and isolated falls are
not, a fall in this study was defined as multiple or recurrent
falls [23,24]. Individual patients reported their history of falls
using standardized questions and were provided with a clear
definition of falls. Other secondary measures were the inci-
dence of fall-related injuries and cumulative fall-related
costs.
2.2.3. The Rotterdam diabetic foot study test battery
The 39-item RDF-39 includes both instruments and test sites
to measure overall foot sensation [8,11]. This scoring system
contains 39 dichotomized items on static- and moving two-
point discrimination (S2PD and M2PD), static one-point dis-
crimination (S1PD), vibration sense, cold stimulus tests, Rom-
berg’s test, experienced numbness, prior diabetic foot ulcer
and prior amputation (Supplementary Table A). The RDF-39
is unidimensional and valid in the assessment of sensation
at the feet [8,11]. S2PD and M2PD were tested with a Disk-
CriminatorTM (US Neurologicals, LLC, Poulsbo, Washington,
USA), with the threshold set at 8 mm, based on previously
published normative values [16]. S1PD was tested with a
10 g Semmes-Weinstein monofilament (Baseline TactileTM,
USA), based on current international standards of medical
care in diabetes [25,26]. S2PD, M2PD and S1PD test sites were
chosen in concordance with the nerve territories of the foot: I,
hallux (medial plantar nerve [tibial nerve]); II, medial heel
(calcaneal nerve [tibial nerve]); III, first dorsal web (deep per-
oneal nerve); IV, lateral foot (sural nerve) and V, fifth toe (lat-
eral planter nerve [tibial nerve]). M2PD was not tested at the
fifth toe due to its small surface area. Vibration sense was
tested with a Rydel-Seiffer tuning fork (Martin, Tuttlingen,
Germany) at the medial malleolus and dorsal interphalangeal
joint of the hallux and compared to normative threshold data
[27]. Cold sensation was tested by applying a cold piece of
metal to the arch of the foot. Information on numbness was
derived from the MNSI, which was administered by the physi-
cian before the physical examination. Information on prior
ulceration and/or amputation, as indicators of severe sensory
loss, was derived from the patient interviews. Sensory test
items constituted of both a sensory test and test location
(e.g. S1PD at the lateral foot (S1PD IV), S2PD at the fifth toe
(S2PD V)). For each RDF-39 item, a score 1 was noted when a
patient scored above the threshold. The maximum score is
39 points (including both ankles and feet), with higher scores
indicative of more severe sensory loss [8,11].
2.3. Statistical analysis
Analyses were based on the 296 included patients who were
assessed at the second follow-up. Baseline characteristics
were presented as mean (SD) for variables with normal distri-
butions, median (IQR) for variables with skewed distributions,
and n (%) for categorical variables. The Shapiro-Wilk test was
used to assess normality. Differences between categories
were assessed using a Kruskal-Wallis test.
2.3.1. Brief-BESTest predictors
Relationships between the Brief-BESTest and baseline contin-
uous predictor variables (RDF-39, MNSI total score, body mass
index (BMI), age and diabetes duration) were explored usingSpearman’s correlation coefficients. Univariate linear regres-
sion analysis was used to explore the relationship between
each potential predictor variable with the Brief-BESTest. Only
baseline variables with a realistic potential contribution to the
outcome variable and availability in the RDF-study dataset
were included in the models (i.e. sex, age, weight, height,
duration and type of diabetes, medical history and pedal sen-
sory status (RDF-39). Significant factors, as determined by a
p < 0.10, were included in the multivariable linear regression
model with backward selection and considered significant
with p < 0.05 (two-sided).
2.3.2. Relationships between Brief-BESTest and falls and
RDF-39 and falls
Receiver operating characteristic analysis and area under the
curves (AUCs) were used to determine the optimal cut-off
points (Youden’s J statistic) of both the RDF-39 and Brief-
BESTest to differentiate individuals with and without a his-
tory of (recurrent) falls (Brief-BESTest) or future falls (RDF-
39) [28]. Prognostic accuracy at the optimal cut-off was
expressed as sensitivity and specificity.
2.3.3. Predictors of falls
A binary logistic regression analysis was used to explore the
relationship between each potential predictor variable with
incident future falls. Again, only variables with a realistic
potential contribution to the outcome variable were included
in the models. Significant factors with p < 0.10 were included
in the multivariable logistic regression model with backward
conditional selection and considered significant with
p < 0.05. When two or more covariables were highly corre-
lated, only one was selected for the analysis to avoid multi-
collinearity. As a result, weight and height were selected
instead of BMI.
2.3.4. Fall- and fracture incidence per person-time
Fall- and fracture incidence was calculated using standard
person-time methods.
All statistical analysis was carried out using IBM SPSS
Statistics 24.0 (IBM Corp., Armonk, New York, USA). P-values
<0.05 (two-sided) were considered statistically significant.3. Results
3.1. Included subjects
Included were 416 subjects. During RDF-study follow-up, 32
patients withdrew from study participation, 66 patients were
lost to follow-up and 22 patients died. The remaining 296
patients (71.2%) were assessed at the second follow-up (med-
ian follow-up: 885 days (IQR): 833-1000). Of these, 134 patients
(65.5%) underwent the balance tests. 255 of 296 patients
(86.1%) were non-fallers and the remaining 41 patients
(13.9%) were recurrent fallers. Table 1 shows the baseline
characteristics of the different groups. Demographic and
anthropometric data were comparable between groups.
Recurrent fallers had more often type 2 diabetes, neuropathy
complaints (MNSI score), increased sensory loss (RDF-39
score) and impaired balance tests (Brief-BESTest).
Table 1 – Baseline and outcome data.
Patients with Brief-BESTest
at second follow-up (n = 134)
Patients without Brief-BESTest
at second follow-up (n = 162)
Non-fallers (second
follow-up) (n = 255)
Recurrent fallers
(second follow-up) (n = 41)
Gender (M/F) 84/59 89/73 152/103 21/20
Age (median (y), IQR) 63.2 (55.2 – 68.6) 64.4 (55.8 – 72.3) 64.0 (55.2 – 69.9) 62.7 (56.6 – 72.2)
Ethnicity (n (%))
- Caucasian
- Indo-Surinamese
- African
- Asian
- Other
116 (86.6%)
8 (3.0%)
4 (3.0%)
3 (2.2%)
3 (2.2%)
130 (80.2%)
16 (9.9%)
5 (3.1%)
3 (1.9%)
8 (4.9%)
211 (82.7%)
21 (8.2%)
9 (3.5%)
6 (2.4%)
8 (3.1%)
35 (85.4%)
3 (7.3%)
-
-
3 (7.3%)
Height (median (m), IQR) 176.0 (167.8 – 183.0) 172.0 (164.0 – 179.0) 175.0 (166.0 – 180.0) 172.0 (164.5 – 181.5)
Weight (median (kg), IQR) 90.0 (79.0 – 106.2) 85.5 (75.0 – 98.2) 87.0 (76.0 – 102.0) 94.3 (77.0 – 113.0)
BMI (median (kg/m2), IQR) 29.7 (26.8 – 34.4) 29.1 (25.6 – 32.5) 29.1 (25.7 – 32.8) 30.9 (27.0 – 36.5)
Duration of diabetes (median (y), IQR) 16.0 (9.0 – 26.0) 16.0 (9.8 – 24.3) 16.0 (9.0 – 26.0) 16.0 (11.0 – 24.5)
Type of diabetes (n (%))
- Type 1
- Type 2
32 (23.9%)
102 (76.1%)
37 (22.8%)
125 (77.2%)
64 (25.1%)
191 (74.9%)
5 (12.2%)
36 (87.8%)
Mean Arterial Pressure (median (mmHg), IQR)
Systolic blood pressure (median (mmHg), IQR)
Diastolic blood pressure (median (mmHg), IQR)
97.2 (91.0 – 103.3)
136.0 (126.8 – 149.3)
77.0 (70.0 – 82.0)
96.7 (88.7 – 104.3)
136.0 (125.0 – 146.0)
77.5 (69.0 – 82.0)
96.7 (89.0 – 103.3)
136.0 (125.0 – 146.0)
77.0 (125.0 – 146.0)
97.3 (90.7 – 106.2)
140.0 (127.0 – 155.0)
77.0 (70.0 – 84.0)
Drugs (n (%))
- Lipid lowering drugs
- Oral blood glucose lowering drugs
- Insulin
80 (59.7%)
76 (56.7%)
109 (56.7%)
107 (66.0%)
88 (54.3%)
141 (87.0%)
166 (65.1%)
143 (56.1%)
216 (84.7%)
21 (51.2%)
21 (51.2%)
34 (82.9%)
Medical history (n (%))
- Hypertension
- Myocardial infarction
- Angina pectoris
- Coronary artery disease
- CABG/PCI
- CVA/TIA
- Cancer
- COPD
- Peripheral arterial disease
83 (61.9%)
14 (10.4%)
12 (9.0%)
18 (13.5%)
13 (9.8%)
14 (10.4%)
14 (10.4%)
15 (11.2%)
7 (5.2%)
91 (56.2%)
26 (16.0%)
21 (13.0%)
39 (24.1%)
37 (22.8%)
14 (8.6%)
22 (13.6%)
12 (7.4%)
11 (6.8%)
144 (43.5%)
29 (11.4%)
25 (9.8%)
44 (17.3%)
37 (14.6%)
26 (10.2%)
30 (11.8%)
23 (9.0%)
15 (5.9%)
30 (73.2%)
11 (26.8%)
8 (19.5%)
13 (31.7%)
13 (31.7%)
2 (4.9%)
6 (14.6%)
4 (9.8%)
3 (7.3%)
Diabetic Sensory Polyneuropathy (n (%))
- MNSI score > 3 53 (41.7%) 54 (41.5%) 82 (36.6%) 25 (75.8%)
Rotterdam Diabetic Foot Study
Test Battery (median score, IQR)
- RDF-39
17.0 (8.0 – 22.0) 14.0 (8.0 – 22.0) 15.0 (7.0 – 21.0) 21.0 (14.5 – 29.5)
Brief-BESTest (median score, IQR) 16.0 (10.0 – 21.3) – 16.5 (11.8 – 22.0) 8.0 (0.50 – 15.0)
Retinopathy (n (%)) 21 (25.0%) 28 (26.7%) 42 (25.8%) 7 (26.9%)
Single fallers (n (%))
Recurrent fallers (n (%))
25 (18.7%)
20 (14.9%)
20 (12.3%)
21 (13.0%)
45 (17.6%)
-
-
41 (100%)
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Fig. 1 shows that RDF-39 and Brief-BESTest total scores were
significantly negatively associated (rs = 0.446, p < 0.0005)
with the RDF-39 sum score, accounting for 21.0% of the vari-
ation in total Brief-BESTest scores with adj. R2 = 20.5%, despite
considerable heterogeneity among patients. A Brief-BESTest
score of 13 points correlates with a RDF-39 score of 22 points.
Table 2 displays the relationship between increasing cate-
gories of RDF-scores, the separate Brief-BESTest subscores
and the total MNSI score. The negative association seen in
Fig. 1 is also present for each of the Brief-BESTest sub scores.
3.1.2. Impact of balance and sensory loss on recurrent falls
The Brief-BESTest had an acceptable ability to differentiate
participants with and without a history of recurrent falls
(AUC (CI) = 0.746 (0.624–0.868)). At the optimal probability cut-
off point of 13 points, the Brief-BESTest yielded a sensitivity of
71.9% (correctly classifying the group with a history of recur-
rent falls during follow-up) and specificity of 70% (correctly
classifying the group without a history of falls during
follow-up).
The baseline RDF-39 score had an acceptable ability to pre-
dict participants with and without future recurrent falls dur-
ing follow-up (AUC (CI) = 0.687 (0.596–0.779)). At the optimal
probability cutoff point of 18 points, the RDF-39 yielded a sen-
sitivity of 70.7% (correctly classifying the group with recurrent
falls during follow-up) and specificity of 60.4% (correctly clas-
sifying the group without falls during follow-up). A total RDF-
39 score of 18 points indicates aberrant S2PD and M2PD mea-
surements, but intact vibration sense and protective sensa-
tion, as assessed with a 10 g monofilament (Fig. 1, Table 2).
3.1.3. Brief-BESTest predictors
Table 3 shows the results of univariate and multivariable lin-
ear regression analysis for total Brief-BESTest scores. A higher
RDF-39 score at study entry (i.e. more severe degree of sensory
loss; beta coefficient: 0.37), a higher age (beta: 0.35 per
year), a higher weight (beta: 0.09 per kilogram), type 2 dia-
betes (beta: 6.59), a medical history of hypertension (beta:
4.80), myocardial infarction (beta: 4.75), COPD (beta:
4.24) or peripheral artery disease (beta: 8.56) significantly
reduced the Brief-BESTest total score at the second follow-
up, implying increased balance impairment. In the multivari-
able analysis, only a higher RDF-39 score at study entry (beta:
0.31), a higher age (beta: 0.21) and height (beta: 0.13) added
independently and significantly to the prediction of the Brief-
BESTest total score (p < 0.0005, adj. R2 = 0.46).
3.1.4. Predictors of falls
Table 4 shows the results of univariate and multivariable bin-
ary logistic regression analysis for recurrent falls. A higher
RDF-39 score (crude OR: 1.08) and a history of myocardial
infarction (crude OR: 2.86) significantly increased the odds
for recurrent falls during follow-up. The multivariable logistic
regression model showed that a higher RDF-39 score (adj. OR:
1.12), male gender (adj. OR: 0.32) and age (adj. OR: 0.94)
remained independently significant predictors for future falls
(model X2(4) = 25.386, p < 0.0005; proportion of cases correctly
classified: 86.2%). The RDF-39 score proved to be an indepen-
6 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 5 8 ( 2 0 1 9 ) 1 0 7 9 3 0dent predictor of recurrent falls (BriefBESTest < 16: OR: 1.08,
p = 0.11 versus BriefBESTest > 15: OR 1.07, p = 0.30).
3.1.5. Incidence of falls, resource use and costs
The incidence of recurrent falls in our cohort was 2.3 falls
(95% CI: 1.6-3.3) per 100 person-years. Thirty-one patients
made use of healthcare resources due to falls by visiting a
general practitioner (n = 6), physiotherapist (n = 3) or were
in need of secondary care (n = 24). Twelve patients (five
women, seven men) suffered from fall-related fractures or
ruptures (0.9 fractures (95% CI: 0.5-1.5) per 100 person-
years). Two hip fractures were observed, one patella fracture,
two broken ankles, one metatarsal bone fracture and two bro-
ken halluces. Upper extremity injuries included a fractured
humerus, a broken wrist, a fractured digitus five and a rup-
ture of the supraspinatus tendon. Total healthcare expendi-
tures were $ 59,947.07, median costs of US$ 440.45 (IQR:
179–1162) per fall (2016 price level).
4. Discussion
Any person older than 65 years who has not fallen in the pre-
vious year has a pre-test probability of 19% to 36% to fall the
next year [29,30]. As a previous fall is a sensitive prognostica-Fig. 1 – The correlation between balance, foot sensation and falls
associated with a history of recurrent falls. A baseline RDF-39 s
The mean Brief-BESTest with 95% confidence intervals is displator of future falls, exploration of its predictors appears sensi-
ble. Previous studies suggest that the highest potential yield
comes from screening on balance and gait, as these factors
are independent predictors of future falls and have more
impact than orthostatic hypotension, visual impairment,
medication use, limitation in activities of daily living and cog-
nitive impairment [31]. This is important, because strategies
to improve gait and balance of patients with diabetes have
been proven effective to avoid falls [31–33]. So far, little atten-
tion has been given to the influence of degree of sensory loss
at the feet in relation to both balance impairment and falls
[12,14]. Our study showed that degree of sensory loss signifi-
cantly relates to the risk for imbalance and risk of falls.
A previous study showed a positive association between
peripheral neuropathy and pedal sensibility on the one hand
and balance on the other, but sensibility was not assessed
using an unambiguously outcome measure [14]. The advan-
tage of the RDF-39 in assessing foot sensation lies in the fact
that both early stages of sensory loss (i.e., S2PD, M2PD) as well
as more advanced stages of sensory loss (e.g. loss of cold sen-
sation, prior ulceration etc.) are measured with validated and
easy to apply screening instruments. The RDF-39, a dichoto-
mized version of the full RDF Study Test Battery, takes around
10 minutes to complete. This information enables quantifica-. ROC-analysis showed that a Brief-BESTest of 13 points was
core of 18 points was associated with future recurrent falls.
yed.
Table 2 – Brief-BESTest and several categories of incremental sensory loss (n = 134 subjects).
Total RDF-39 score* Intact sensation
(RDF-39: 0), n = 1
Loss of S2PD
and/or M2PD
(RDF-39: 1  18), n = 80
Loss of vibration sense
(RDF-39: 19  22), n = 24
Loss of protective
sensation (plantar)
(RDF-39: 23  29), n = 16
Aberrant Romberg test.
Insensate to cold stimulus.
Prior ulcer or amputation
(RDF-39: 30  39), n = 13
P-value
Median total Brief-BESTest score (IQR) 24 (0) 18 (10.5) 15.5 (10) 14 (11.25) 3 (11) < 0.0005#
Median sub-scores (IQR)
Section I: Biomechanical constraints 3 (0) 3 (1) 2 (2) 2 (3) 1 (2) < 0.0005#
Section II: Stability limits 3 (0) 3 (1) 2 (1) 2.5 (1) 2 (2) 0.003#
Section III: Transitions-Anticipatory Postural adjustment
- Left 3 (0) 2 (2) 1.5 (1) 1 (1.75) 0 (1) < 0.0005#
- Right 3 (0) 2 (2) 1 (1) 1 (1.75) 0 (0) < 0.0005#
Section IV: Reactive Postural Response
- Left 3 (0) 3 (3) 2.5 (3) 2.5 (3) 0 (0.5) 0.075#
- Right 3 (0) 2 (3) 1 (3) 0.5 (3) 0 (0.5) 0.058#
Section V: Sensory orientation 3 (0) 3 (1) 1 (3) 1 (2.75) 0 (2) 0.001#
Section VI: Stability in gait 3 (0) 3 (0) 3 (0) 3 (0.75) 0 (3) < 0.0005#
Total MNSI score (IQR) 3 (0) 2 (3) 3 (5) 5 (3.75) 8 (4) < 0.0005#
A higher RDF-39 score indicates a higher degree of sensibility loss. A higher Brief-BESTest score indicates less balance impairment.
RDF-39, 39-item Rotterdam Diabetic Foot Study Test Battery.
* See Supplementary Table A; IQR, inter-quartile range.
# Kruskal-Wallis test; MNSI, Michigan Neuropathy Screening Instrument.
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Table 3 – Univariate and multivariable linear regression analysis of balance status at second follow-up.
Univariate model
B (95% CI) P-value
Multivariable model
B (95% CI) P-value
Male sex 1.002 (1.594 to 3.598) 0.446
Age (years) 0.346 (0.445 to 0.246) <0.0005 0.210 (0.349 to 0.072) 0.003
Weight (kg) 0.091 (0.146 to 0.036) 0.001
Height (cm) 0.075 (0.045 to 0.195) 0.218 0.134 (0.018 to 0.250) 0.024
Duration of diabetes (years) 0.034 (0.066 to 0.133) 0.503
Diabetes type 2 6.589 (9.313 to 3.864) <0.0005 2.924 (6.164 to 0.316) 0.076
Medical history
- Hypertension
- Myocardial infarction
- Angina pectoris
- CVA/TIA
- Cancer
- COPD
- Emphysema
- Peripheral artery disease
- Retinopathy
4.804 (7.260 to 2.348)
4.754 (8.785 to 0.722)
2.816 (7.213 to 1.581)
3.956 (8.013 to 0.101)
3.398 (7.469 to 0.674)
4.236 (8.159 to 0.312)
1.856 (12.228 to 8.516)
8.561 (14.021 to 3.102)
1.429 (5.112 to 2.255)
<0.0005
0.021
0.207
0.056
0.101
0.035
0.724
0.002
0.443
3.271 (7.044 to 0.501) 0.088
Rotterdam Diabetic Foot Study Test Battery (score)
- RDF-39 0.366 (0.487 to 0.244) <0.0005 0.307 (0.462 to 0.152) <0.0005
Dependent variable: Brief-BESTest total score (a higher score indicates less balance impairment); B, beta coefficient; CI, confidence interval;
CVA, cerebrovascular accident; TIA, transient ischemic attack; COPD, chronic obstructive pulmonary disease; RDF-39, 39-item Rotterdam
Diabetic Foot Study Test Battery.
Table 4 – Univariate and multivariable binary logistic regression analysis on risk of future falls at second follow-up.
Univariate model
OR (95% CI)
P-value Multivariable model
OR (95% CI)
P-value
Male sex 0.712 (0.364 to 1.379) 0.313 0.319 (0.126 to 0.811) 0.016
Age (years) 1.003 (0.975 to 1.031) 0.844 0.938 (0.899 to 0.979) 0.003
Weight (kg) 1.009 0.261
Height (cm) (0.994 to 1.024)
0.992 (0.961 to 1.025)
0.642
Duration of diabetes (years) 0.996 (0.969 to 1.024) 0.783
Diabetes type 2 2.413 (0.908 to 6.411) 0.077 3.157 (0.804 to 12.398) 0.100
Medical history
- Hypertension 2.102 (1.009 to 4.379) 0.047
- Myocardial infarction 2.857 (1.295 to 6.307) 0.009
- Angina pectoris 2.221 (0.925 to 5.331) 0.074
- CVA/TIA 0.452 (0.103 to 1.980) 0.292
- Cancer 1.286 (0.499 to 3.312) 0.603
- COPD 1.090 (0.357 to 3.332) 0.879
- Peripheral artery disease 1.263 (0.349 to 4.570) 0.722
- Retinopathy 1.061 (0.417 to 2.704) 0.901
Rotterdam Diabetic Foot Study Test Battery (score)
- RDF-39 1.080 (1.040 to 1.121) <0.0005 1.124 (1.056 to 1.196) <0.0005
Dependent variable: incidence of recurrent falls; OR, odds ratio; CI, confidence interval; CVA, cerebrovascular accident; TIA, transient ischemic
attack; COPD, chronic obstructive pulmonary disease; RDF-39, 39-item Rotterdam Diabetic Foot Study Test Battery.
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Moreover, this study showed that at a cut-off of 18 points,
patients become at increased risk for recurrent falls.
We used the Brief-BESTest to measure balance, of which
reliability and its ability to discriminate between patients
with and without a history of falls have been demonstrated
[18,19]. Current study adds that the total Brief-BESTest score
is also able to differentiate a history of recurrent fall statuswith favorable test characteristics when using a cut-off value
of 13 points. Moreover, we found that the Brief-BESTest score
is predominantly influenced by pedal sensation.
Neuropathy has long been considered the most dominant
predictor of falls in diabetes, because diminishing
somatosensory function of the lower extremity reduces the
ability to detect changes in balance and make the necessary
adjustments to avoid falls [35]. Yet, the basis of propriocep-
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 5 8 ( 2 0 1 9 ) 1 0 7 9 3 0 9tion is related to cutaneous afferents, rather than joint affer-
ents. Therefore, we restricted our attention in this study to
cutaneous sensation [36]. Previous studies reported the influ-
ence of retinopathy and cataracts on contrast sensitivity and
its contribution to balance impairments, which is important
especially in low light conditions (e.g. bathroom visits at
night) [37,38]. Only three out of 11 studies from the literature
found visual impairment a statistically significant factor of
the occurrence of falls (ORs ranging 1.6–2.0). We found that
retinopathy was not significantly associated with the Brief-
BESTest score or with falls. This suggests that it is not
retinopathy alone and decreased foot sensation, rather than
ocular changes, that is more likely to be responsible for bal-
ance impairment and associated with falls. Previous research
has shown that vestibular dysfunction is 2.6 times more likely
to be related to falls in the previous year [39]. However, the
influence of diabetes on the quality and availability of
vestibular information to the vestibulo-spinal tract to relay
motor commands has not been examined in our study and
may be accounted for in future studies [2,40].
In our study, the estimated incidence of falls was 2.3 per
100 person-years, which is less than other reports (125 per
100 person-years). This is mainly due to the unselected popu-
lation of patients included in the RDF-study (both neuro-
pathic and non-neuropathic subjects), compared to a study
of patients with prior foot ulcers only (indicative of end-
stage sensory loss) [22]. Our study also showed that falls lead
to considerable burden for society. Falls account for approxi-
mately 10% of emergency department visits among elderly
persons, with a strong age gradient. One in ten falls results
in serious injury, such as fractures and brain or head injuries
[30,41]. In the Dutch healthcare setting, average costs per fall
were estimated to be € 9370 (2009 price level), which increased
with being female, a higher age and comorbidity [41]. A US
study found average costs per fall of US$ 9463 (2015 price
level) [42]. In our study, we found lower costs, most likely
related to the less serious or non-fatal injuries observed, dif-
ferences in healthcare systems and the overall higher costs of
healthcare in the United States. Moreover, we only included
in-hospital costs, while out-of-hospital care (e.g. nursing
homes) are known to account for considerable additional
costs of approximately one-third of total costs [41].
Strengths of our study are the relatively large sample size,
the prospective study design in an unselected group of
patients with diabetes with substantial follow-up and the
appreciation of pedal sensation as a new and valid measure
of neuropathy instead of the conventional assessment of
symptoms of neuropathy [15]. Several caveats relating to
our study are important to highlight. Firstly, results of retro-
spective assessment of patients’ fall status annually may
have been sensitive to recall bias with a reported specificity
of 91–95% and sensitivity of 80–89% when recalling falls in
the previous year [43]. Secondly, selection bias may have
played a role since 120 patients dropped-out from study start
(n = 416) and 134 patients measured with the Brief-BESTest.
However, the impact of selection bias appears limited. Selec-
tion bias due to mortality is likely to be absent as patients
who died during follow-up had a slightly higher RDF-39 score
at baseline, but this effect is explained by the correlation of a
higher age and RDF-39 score. Withdrawals (n = 32) andpatients lost-to-follow-up (n = 66) did not significantly differ
with patients available for follow-up regarding age and dura-
tion of diabetes. Overall, sample size was sufficient to answer
our hypothesis without the risk of under power with estima-
tions unlikely to change with higher patient numbers tested.
Thirdly, prognostic characteristics of RDF-39 and Brief-
BESTest could not be compared head-to-head because the lat-
ter was not measured at study entry. Yet, the observed asso-
ciation between pedal sensory loss and balance deserves
further investigation.
In summary, assessment of patient’s sensory loss using
the total RDF-39 score may help clinicians to better stratify
patients at risk for balance impairment and falls. Patients
already become at risk when having lost two-point discrimi-
nation. This information is important regarding patient infor-
mation and may be used in recommendations on specific
intervention strategies to prevent falls. One such intervention
is decompressing lower extremity peripheral nerves in
selected patients, which has been shown to restore sensation
and improves balance [44,45]. We conclude that patients with
loss of vibration sense should be subjected to a multifactorial
falls risk assessment for prevention that includes gait and
balance testing. The model suggests that patients can be cat-
egorized in medium and high-risk categories, which might be
helpful in tailored preventive interventions.Guarantor’s statement
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